Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650865 | 0.94 | CYP4F2 (0.43) | CYP4F2CYP4A11TSHRDGAT1ACLY | |
| SCHEMBL9129151 | 0.92 | CYP4F2 (0.46) | CYP4F2CYP4A11TSHRDGAT1ACLY | |
| SCHEMBL8986987 | 0.92 | CYP4F2 (0.46) | CYP4F2CYP4A11TSHRDGAT1ACLY | |
| SCHEMBL8987098 | 0.92 | CYP4F2 (0.46) | CYP4F2CYP4A11TSHRDGAT1ACLY | |
| SCHEMBL1661232 | 0.86 | DGAT1 (0.38) | CYP4F2CYP4A11TSHRDGAT1 | |
| SCHEMBL1855321 | 0.83 | TSHR (0.36) | TSHRDGAT1 | |
| SCHEMBL2022397 | 0.81 | DGAT1 (0.44) | CYP4F2CYP4A11TSHRDGAT1 | |
| SCHEMBL8433296 | 0.81 | TSHR (0.56) | CYP4F2CYP4A11TSHR | |
| SCHEMBL6080261 | 0.81 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT1ACLY | |
| SCHEMBL9482334 | 0.81 | CYP4F2 (0.47) | CYP4F2CYP4A11ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504436-A | Improved preparation method of gemfibrozil intermediate | 山东精进药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-4259605-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | Astrazeneca AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| CN-116547270-A | 4- (2-fluoro-4-methoxy-5-3- (((1-methylcyclobutyl) methyl) carbamoyl) bicyclo [2.2.1] hept-2-yl) carbamoyl) phenoxy) -1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as RXFP1 modulators for the treatment of heart failure | 阿斯利康(瑞典)有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-20230078576-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-03-16 | — | — | US | disclosed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | disclosed |
| WO-2022122773-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2020212955-A1 | PROCESS FOR THE PREPARATION OF A KEY INTERMEDIATE OF GEMFIBROZIL | HIKAL LIMITED (IN) | 2020-10-22 | — | — | WO | disclosed |
| US-4107191-A | PROSTAGLANDINS, BLOOD PRESSURE LOWERING, LABOR INDUCTION, REPRODUCTIVE-CYCLE REGULATION, GASTRIC ANTISECRETORY | THE UPJOHN COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
| US-4104474-A | PROSTAGLANDINS, HYPOTENSIVE, OXYTOCICS, ANTIFERTILITY, ANTISECRETORY | THE UPJOHN COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
| US-4099014-A | BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4099015-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4086258-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-04-25 | — | — | US | disclosed |
| US-4033989-A | 9-Deoxy-PGF2 Analogs | THE UPJOHN COMPANY (US) | 1977-07-05 | — | — | US | disclosed |
| US-4029681-A | 13,14-Didehydro-PG analogs | THE UPJOHN COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
| US-4026909-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
| US-4018803-A | 13,14-Didehydro-PG3 compounds | THE UPJOHN COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4016184-A | PROSTAGLANDINS, BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667602-B2 | Compounds and their use | RXFP1, RXFP3, RXFP2 | CYP4F2 179/4885CYP4A11 663/4885TSHR 436/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | CYP4F2 179/4885CYP4A11 663/4885TSHR 436/4885 |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | CCNE2, CCNE1, CCNT1 | CYP4F2 53/4885CYP4A11 56/4885TSHR 3371/4885 |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | CCNE2, CCNE1, CCNT1 | CYP4F2 53/4885CYP4A11 56/4885TSHR 3371/4885 |
| US-20230078576-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | CYP4F2 179/4885CYP4A11 663/4885TSHR 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.